Melbourne researchers have uncovered genes responsible for the way the body fights infection at the point of ‘invasion’ – whether it’s the skin, liver, lungs or the gut.
Research led by Dr Axel Kallies and Dr Klaas van Gisbergen at the Walter and Eliza Hall Institute of Medical Research, and Dr Laura Mackay from the University of Melbourne at the Peter Doherty Institute for Infection and Immunity has identified the genes Hobit and Blimp1 and found that they control a universal molecular program responsible for placing immune cells at the ‘front lines’ of the body to fight infection and cancer.
The presence of these organ-residing cells, which differ strikingly from their counterparts circulating in the blood stream, is key to local protection against viruses and bacteria.
Walter and Eliza Hall Institute’s Dr Kallies said the human body was fighting disease-causing pathogens every minute of its life. Dr Kallies said identifying how immune cells remain in the part of the body where they are needed most was critical to developing better ways to protect us from infections such as malaria or HIV.
“Discovering these ‘local heroes’ and knowing how the localised immune response is established allows us to find ways to ensure the required cells are positioned where they are needed most,” Dr Kallies said.
“This research will help us understand how immune cells adapt, survive and respond within the organs they protect. This is critical to rid the body of pathogens even before they are established and may also have implications for understanding how the spread of cancer could be prevented.”
The Doherty Institute’s Dr Laura Mackay, who is also an associate investigator with the Australian Research Council Centre of Excellence in Advanced Molecular Imaging, said the factors that control the ‘tissue-residency’ of immune cells – their ability to locally reside in different organs of the body – was previously unknown.
“These results have major implications for developing strategies to induce immune cells in tissues that protect against infectious diseases,” Dr Mackay said.
“It’s a crucial discovery for future vaccine strategies – Hobit and Blimp1 would be key to placing immune cells in the tissues, which we know are really important for protection.”
The Latest on: Localised immune response
via Google News
The Latest on: Localised immune response
- Targeted radionuclide therapy enhances prostate cancer response to immunotherapieson July 13, 2020 at 6:49 am
which has been shown to remodel the tumor microenvironment of irradiated tumors to make them more immune-susceptible even at low radiation doses, is limited to the localized disease setting.
- We have done extraordinarily well, but no part of the nation is immuneon July 13, 2020 at 12:47 am
Australia is one of the world’s leading nations in our response to the COVID-19 ... Alex Ellinghausen It’s important to be honest and upfront – no part of Australia is immune. Australia has done ...
- Karen Autio, MD, MSc, on Potential Role of CPIs in Prostate Canceron July 9, 2020 at 1:37 pm
In the following interview, Karen A. Autio, MD, MSc, of Memorial Sloan-Kettering Cancer Center in New York City, answered questions about the review, which was titled "Immune Checkpoint Blockade for ...
- Faulty immune response to SARS-CoV-2 one of the main causes of deathon July 6, 2020 at 11:05 pm
A new study published on the preprint server medRxiv in July 2020 describes the organ and tissue-specific spread of the virus causing the current COVID-19 pandemic, severe acute respiratory syndrome ...
- Gastrointestinal Manifestations of Food Allergyon July 4, 2020 at 5:00 pm
Food allergy is an adverse immune response to food protein(s ... Oral allergy syndrome: symptoms are localized to oropharynx (angioedema). The offenders are pollen proteins that cross-react ...
- AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Researchon July 2, 2020 at 6:59 am
AffyImmune Therapeutics, Inc. disclosed novel advancements in their proprietary affinity-tuned CAR T-cell programs and technology in three presentations at the recent Annual Meeting of the American ...
- Bolt Biotherapeutics Closes $93.5 Million Series C Financingon July 1, 2020 at 5:46 am
In preclinical models, systemic administration of HER2-ISACs demonstrate localized immune activation ... potential for durable and meaningful responses for HER2-expressing cancers. About Bolt ...
- Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastaseson June 25, 2020 at 12:30 am
We look forward to exploring Annamycin's clinical potential to target tumors localized in the lungs ... while also stimulating a natural immune response, being studied for brain tumors, pancreatic ...
- How a Bee Sting Allergy Can Cause Life-Threatening Symptoms, According to a Doctoron June 24, 2020 at 12:15 pm
But being stung by a bee—even if you’re allergic—doesn’t have to induce panic, according to board-certified allergist Lakiea Wright, M.D., medical director of Thermo Fisher’s Scientific ...
- Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancieson June 24, 2020 at 1:00 am
ALPN-202 is a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor - SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences ... clinical relevance of localized CD28 costimulation ...
via Bing News